Equol and Equol Analogs for Radiation Protection ID: 2019-011

This invention offers a novel approach to protect mammals from the adverse effects of radiation exposure using equol and its analogs.

Technology Overview

The invention introduces methods for the administration of equol (racemic or non-racemic), equol analogs, and combinations with other polyphenolic compounds like resveratrol to prevent and treat the effects of radiation exposure. It is applicable in medical, dental, and environmental scenarios involving both low-dose and high-dose radiation exposure, aiming to mitigate health risks associated with radiation such as cancers, DNA mutations, and more.

Key Advantages

• Protection against a wide range of radiation-induced health risks, including cancers, DNA mutations, and premature aging
• Various methods of administration (oral, topical, trans-dermal, injectable, food, supplements) cater to different needs and scenarios
• Equol demonstrates potent antioxidant and anti-inflammatory activities, contributing to decreased cell damage and inhibition of neoplastic growth
• Unique delivery profile through skin layers, forming an epidermal reservoir, unlike other polyphenolic compounds

Problems Addressed

• Radiation-induced health risks such as cancers, DNA mutations, radiation burns, and premature aging
• Insufficiency of dietary sources in providing adequate radiation protection
• Lack of effective treatments that address both low-dose and high-dose radiation exposure scenarios

Market Applications

• Medical radiation therapy and diagnostics requiring radiation exposure protection
• Dental practices involving routine use of radiographic imaging
• Environmental and occupational scenarios with exposure to radiation
• Supplements and products aimed at individuals at risk of radiation exposure

Additional Information

Technology ID: 2019-011
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025